CN105595346B - 一种用于补钙的液体制剂及其制备方法 - Google Patents
一种用于补钙的液体制剂及其制备方法 Download PDFInfo
- Publication number
- CN105595346B CN105595346B CN201510547249.9A CN201510547249A CN105595346B CN 105595346 B CN105595346 B CN 105595346B CN 201510547249 A CN201510547249 A CN 201510547249A CN 105595346 B CN105595346 B CN 105595346B
- Authority
- CN
- China
- Prior art keywords
- calcium
- replenishing
- liquid preparation
- solution
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 111
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 110
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 95
- 239000007788 liquid Substances 0.000 title claims abstract description 82
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004471 Glycine Substances 0.000 claims abstract description 22
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 16
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 8
- 108010011485 Aspartame Proteins 0.000 claims abstract description 8
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 8
- 229960003438 aspartame Drugs 0.000 claims abstract description 8
- 235000010357 aspartame Nutrition 0.000 claims abstract description 8
- 239000000605 aspartame Substances 0.000 claims abstract description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 8
- 239000001259 polydextrose Substances 0.000 claims abstract description 8
- 229940035035 polydextrose Drugs 0.000 claims abstract description 8
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 8
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 8
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 8
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 8
- 230000000295 complement effect Effects 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 43
- 230000001954 sterilising effect Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 238000007689 inspection Methods 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 13
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 238000004090 dissolution Methods 0.000 claims description 8
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 7
- 239000001639 calcium acetate Substances 0.000 claims description 7
- 235000011092 calcium acetate Nutrition 0.000 claims description 7
- 229960005147 calcium acetate Drugs 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 229940098462 oral drops Drugs 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 abstract description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 208000019505 Deglutition disease Diseases 0.000 abstract description 6
- 230000037182 bone density Effects 0.000 abstract description 6
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 229960005069 calcium Drugs 0.000 description 91
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 36
- 229910000019 calcium carbonate Inorganic materials 0.000 description 18
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 7
- 229940100688 oral solution Drugs 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 206010006956 Calcium deficiency Diseases 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003913 calcium metabolism Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002133 sample digestion Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- -1 calisanin Chemical compound 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
剂量组 | 动物数(只) | 始重(g) | 终重(g) | 增重(g) |
实施例1 | 10 | 71.5±2.0 | 505.8±34.1 | 434.3±36.2 |
实施例2 | 10 | 73.5±3.0 | 515.1±32.2 | 441.6±40.7 |
实施例3 | 10 | 70.8±3.2 | 517.1±30.8 | 446.3±35.8 |
实施例4 | 10 | 71.4±2.8 | 514.1±32.5 | 442.7±29.5 |
实施例5 | 10 | 73.4±2.1 | 504.3±33.2 | 430.9±27.4 |
基础饲料组 | 10 | 71.6±3.0 | 441.1±32.4 | 369.5±31.2 |
碳酸钙对照组 | 10 | 72.5±2.8 | 475.7±33.8 | 403.2±33.7 |
剂量组 | 动物数(只) | 摄入钙(mg/d) | 粪钙(mg/d) | 表现吸收率 |
实施例1 | 10 | 220.7±17.5 | 60.4±9.5 | 73.5±7.2 |
实施例2 | 10 | 215.8±18.8 | 30.8±10.9 | 78.8±5.8 |
实施例3 | 10 | 221.7±15.4 | 44.6±13.7 | 80.5±3.2 |
实施例4 | 10 | 216.4±19.7 | 47.8±12.1 | 77.7±6.1 |
实施例5 | 10 | 218.7±14.5 | 56.2±18.3 | 74.5±8.5 |
基础饲料组 | 10 | 78.4±8.3 | 24.5±17.0 | 70.2±4.8 |
碳酸钙对照组 | 10 | 209.7±19.5 | 48.8±15.4 | 62.4±8.5 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547249.9A CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547249.9A CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105595346A CN105595346A (zh) | 2016-05-25 |
CN105595346B true CN105595346B (zh) | 2018-12-11 |
Family
ID=55976149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510547249.9A Active CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105595346B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107411096A (zh) * | 2017-05-17 | 2017-12-01 | 悦康动力(北京)科技有限公司 | 一种高钙含量液态补钙制剂及其制备方法 |
CN112370467A (zh) * | 2019-11-05 | 2021-02-19 | 广州富诺营养科技有限公司 | 一种含有铁、锌、钙的滴剂及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032037A1 (en) * | 1999-11-01 | 2001-05-10 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
JP2010126431A (ja) * | 2008-12-01 | 2010-06-10 | Fukuei Hiryo Kk | アミノ酸キレートカルシウム含有液体肥料 |
CN101531609A (zh) * | 2009-04-15 | 2009-09-16 | 无锡市祖平食品科技有限公司 | 一种甘氨酸钙的制备方法 |
CN102526009A (zh) * | 2012-02-21 | 2012-07-04 | 常熟市方塔涂料化工有限公司 | 一种葡萄糖酸钙锌口服溶液 |
CN103690559A (zh) * | 2014-01-05 | 2014-04-02 | 刘春华 | 补充剂钙镁铁锌的制剂类型及其中口服液制备方法 |
CN104489701A (zh) * | 2014-12-10 | 2015-04-08 | 常州兆阳光能科技有限公司 | 补钙保健营养液 |
-
2015
- 2015-09-01 CN CN201510547249.9A patent/CN105595346B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105595346A (zh) | 2016-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108553355A (zh) | 一种复方鱼腥草口腔抑菌清新喷雾剂及其制备方法 | |
CN109700011A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN106723021A (zh) | 一种改善睡眠的功能性食品 | |
JPWO2007091707A1 (ja) | 骨疾患の予防及び/又は治療用医薬組成物、その組成物を含有する機能性食品、健康食品及び医薬製剤、並びに歯根−歯周組織形成促進剤 | |
CN107691838A (zh) | 宠物绝育缓释膏及其制备方法 | |
CN105595346B (zh) | 一种用于补钙的液体制剂及其制备方法 | |
CN104146260B (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN108497498A (zh) | 一种解酒护肝的功能性食品及其制备方法 | |
CN102085356A (zh) | 一种用于增加骨密度的组合物及其制备方法 | |
JP6147193B2 (ja) | 粘土及び蜂花粉系組成物、その調製方法、並びにその栄養学的使用及び治療的使用 | |
CN106138005B (zh) | 一种泡腾效果好的碳酸钙维生素c泡腾片及其制作方法 | |
CN114885999A (zh) | 一组花草茶及其制备方法和用途 | |
CN108498535A (zh) | 一种用于治疗皮肤及黏膜感染的聚维酮碘药物组合物及其制备方法和应用 | |
Gubernick et al. | " Resource" exchange in the biparental California mouse (Peromyscus californicus): water transfer from pups to parents. | |
Ashby | The diseases of children | |
CN102475201A (zh) | 一种具有保健功能的蛋白粉组合物 | |
CN109805390A (zh) | 一种神经酸钙、神经酸锌及维生素k2复合物软胶囊 | |
CN105476953B (zh) | 一种用于补铁的液体制剂及其制备方法 | |
HELLSTRöM | Studies on fluoride distribution in infants and small children | |
CN112675194A (zh) | 一种补钙组合物 | |
CA2192071C (en) | Putamen ovi | |
CN103340402B (zh) | 花生红枣木耳膏、其制备方法及用途 | |
CN103006921A (zh) | 一种对心脑血管缺氧及人体过量氧化毒性有保健作用的组合物及其制备方法 | |
CN112891366B (zh) | 一种治疗绝经后骨质疏松症的中药活性成分组方及其应用 | |
Uffelmann | Manual of the Domestic Hygiene of the Child: For the Use of Students, Physicians, Sanitary Officials, Teachers, and Mothers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Zhang Wei Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Wei Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190114 Address after: 102446 110m of Xiaoying Village Committee, Liangxiang Township, Fangshan District, Beijing Patentee after: Congrui Huikang (Beijing) Technology Development Co., Ltd. Address before: Room 302, Building 1, Gongxing Garden, Liangxiang, Fangshan District, Beijing Patentee before: Zhang Wei |